San Carlos, Calif., March 26,2024 – Alessa Therapeutics Inc. today announced that they will be presenting a poster at the 2024 annual European Association of Urology (EAU) annual meeting in Paris, FR.
Poster Title: A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate Cancer
Session Date and Time: Sunday 07 April 2024, 15:45 – 17:15,
Location: Purple Area, N01; Published Abstract Number: A0677
About Alessa Therapeutics
Founded in 2018 and based on technology developed at the UCSF, Alessa Therapeutics is a privately held company focused on developing selective and sustained localized drug delivery for early interception of cancer. Alessa is financed by Mission BioCapital. For more information on Alessa Therapeutics, visit www.alessatherapeutics.com or email alessa@alessatherapeutics.com.